UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                    FORM 8-K

                                 CURRENT REPORT
                       Pursuant to Section 13 OR 15(d) of
                       The Securities Exchange Act of 1934

       Date of Report (Date of earliest event reported): February 12, 2007


                            PRO-PHARMACEUTICALS, INC.
--------------------------------------------------------------------------------
             (Exact name of registrant as specified in its charter)


          Nevada                    000-32877                    04-3562325
--------------------------------------------------------------------------------
(State or other jurisdiction       (Commission                 (IRS Employer
     of incorporation)             File Number)              Identification No.)

       7 Wells Avenue, Newton, Massachusetts                       02459
     (Address of principal executive offices)                    (Zip Code)

       Registrant's telephone number, including area code: (617) 559-0033


--------------------------------------------------------------------------------
                                       Not Applicable
                              ---------
         (Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:

[ ] Written communications pursuant to Rule 425 under the Securities Act
    (17 CFR 230.425)

[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act
    (17 CFR 240.14a-12)

[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange
    Act (17 CFR 240.14d-2(b))

[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange
    Act (17 CFR 240.13e-4(c))

Item 8.01 Other Events.

On February 12, 2007, Pro-Pharmaceuticals, Inc. issued a news release announcing
it has requested a meeting with the U.S. Food & Drug  Administration  to discuss
the filing of a New Drug  Application for  co-administration  of DAVANAT(R) with
5-Fluorouracil for treatment of cancer patients.  A copy of  Pro-Pharmaceuticals
news  release is attached as Exhibit 99.1 hereto and  incorporated  by reference
herein.

Item 9.01 Financial Statements and Exhibits.

     (c) Exhibits
99.1  News release of Pro-Pharmaceuticals, Inc. dated February 12, 2007.



                                    SIGNATURE

     Pursuant to the  requirements  of the Securities  Exchange Act of 1934, the
registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned thereunto duly authorized.


                                                PRO-PHARMACEUTICALS, INC.


                                                By: /s/ David Platt
                                                    ----------------------------
                                                     David Platt
                                                     Chief Executive Officer

Date:  February 12, 2007